MHC-I-Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy [0.03%]
由MHC-I驱动的抗肿瘤免疫平衡放射性药物治疗的低吸收剂量
Julie Constanzo,Aliasghar Parach,Timothee David et al.
Julie Constanzo et al.
Preclinical and clinical studies increasingly show that the immune response plays a major role in radiotherapy. Here, we investigated the role of major histocompatibility complex class I (MHC-I) molecules recognized by cytotoxic CD8+ T cell...
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy [0.03%]
PSMA放射药物治疗时代前列腺癌的治疗格局
Fabio Turco,Silke Gillessen,Ken Herrmann et al.
Fabio Turco et al.
The treatment landscape of prostate cancer is quite complex because of the many therapeutic options available in different disease settings (hormonal treatments, chemotherapy, poly(adenosine diphosphate ribose) polymerase inhibitors, radiop...
Margaret B Allison,Ciprian Catana,Iris Y Zhou et al.
Margaret B Allison et al.
Fibrosing lung diseases affect over 160,000 individuals in the United States alone and can carry a prognosis that is worse than many cancers. Antifibrotic treatments modify only the rate of fibrosis progression, and more effective therapies...
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer [0.03%]
FDG PET代谢参数在不能手术的III期非小细胞肺癌患者接受42 Gy放化疗前后的预后价值
Pierre Vera,Philippe Giraud,Sébastien Hapdey et al.
Pierre Vera et al.
The purpose of this study was to assess the prognostic value of 18F-FDG PET parameter variation between baseline and 42 Gy (PET2) of radiochemotherapy at 6 mo and 1 y of evaluation in patients with stage III inoperable nonsmall cell lung ca...
An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 4: Impact of Fitting Functions in Estimated Absorbed Doses [0.03%]
一项关于剂量计算变异影响因素的国际研究第四部分：拟合函数对估算吸收剂量的影响
Sara Kurkowska,Julia Brosch-Lenz,Yuni K Dewaraja et al.
Sara Kurkowska et al.
Individualized radiopharmaceutical therapies guided by patient-specific absorbed dose (AD) assessments using nuclear medicine imaging have the potential to improve both efficacy and safety. Understanding sources of variability in AD calcula...
Leah Gajecki,Irina V Lebedeva,Yu-Rou Liao et al.
Leah Gajecki et al.
Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor frequently expressed in solid malignancies, such as glioblastoma and melanoma, with limited expression in healthy tissue, rendering it an ideal target for noninvasive and sp...
Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better [0.03%]
神经母细胞瘤的治疗诊断：使分子放射疗法有更好的效果
Peter J Gawne,Helen E Bryant,Steven G DuBois et al.
Peter J Gawne et al.
Despite improvements in neuroblastoma treatment, survival figures lag behind those of many other childhood malignancies. New treatments, and better use of existing treatments, are essential to reduce mortality. Neuroblastoma expresses sever...
Artificial Intelligence-Enhanced Perfusion Scoring Improves the Diagnostic Accuracy of Myocardial Perfusion Imaging [0.03%]
人工智能增强的灌注评分可提高心肌灌注成像的诊断准确性
Robert J H Miller,Paul Kavanagh,Mark Lemley et al.
Robert J H Miller et al.
We previously demonstrated that a deep learning (DL) model of myocardial perfusion SPECT imaging improved accuracy for detection of obstructive coronary artery disease (CAD). We aimed to improve the clinical translatability of this artifici...
PET Imaging of PD-L1 Occupancy for Preclinical Assessment of the Efficacy of Combined Anti-PD-L1 Immunotherapy and Targeted Therapy [0.03%]
用于评估联合抗PD-L1免疫治疗和靶向治疗疗效的PD-L1占有率的PET显像技术
Céline Chevaleyre,Léa Zimmermann,Simon Specklin et al.
Céline Chevaleyre et al.
The development of resistance significantly hampers the efficacy of immunotherapies in cancer treatment. The combination of JQ1, a BRD4 protein inhibitor, and anti-programmed death ligand 1 (PD-L1) immunotherapies has a synergic therapeutic...
Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series [0.03%]
接受[177Lu]Lu-PSMA治疗后转移性去势抵抗性前列腺癌患者的治疗相关髓系肿瘤：病例系列报告
Michal Eifer,Duncan E K Sutherland,Isaac Goncalves et al.
Michal Eifer et al.
[177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy has a favorable toxicity profile in patients with metastatic castration-resistant prostate cancer (mCRPC). Therapy-related myeloid neoplasm (t-MN) has been described after [177Lu]L...